Skip to main content

Featured

5 Things to Know Today — Oil Diplomacy, TSX Rally, Carney at UNGA, Bond Yields, Canada's AI Gap (Sept. 23, 2026)

  Wednesday, September 23, 2026  |  MoneySavings.ca Oil is pulling back. The TSX is rebounding. Carney is talking deals in New York. And two under-the-radar stories — bond yields creeping up and a warning about Canada's AI ambitions — could quietly reshape your finances. Here's what matters today. 01 of 05 Oil Drops Below $92 as US–Iran Talks Begin at the UN WTI crude pulled back toward $90 per barrel Wednesday — its lowest level since early September — as diplomacy replaced missiles at the United Nations General Assembly in New York. US envoys Jared Kushner and Steve Witkoff spent three hours in shuttle talks with Iranian officials on the UNGA sidelines, just hours after President Trump threatened Iran with "annihilation" in his address to the General Assembly. Iran had offered to reopen the Strait of Hormuz within seven days if the US agreed to ease its naval blockade. Brent settled down roughly 3–4%, snapping five days of decline but still elevated from pre-conflic...
Post a Comment
Read more

article

Labels

Alzheimer’s vaccines get a boost from new drug approval

 

After decades of disappointment and controversy, the field of Alzheimer’s disease research has finally seen a breakthrough with the approval of the first drug that targets the underlying pathology of the condition. 

Aducanumab, a monoclonal antibody that clears amyloid plaques from the brain, was granted accelerated approval by the US Food and Drug Administration in June 2021, despite mixed results from clinical trials and objections from some experts. 

The drug’s approval has rekindled interest in other therapeutic approaches that aim to prevent or slow down the progression of Alzheimer’s, such as vaccines that stimulate the immune system to attack amyloid or tau, another protein that accumulates in the brains of people with the disease. 

Several vaccine candidates are currently in various stages of development and testing, and some researchers are optimistic that they could offer a more effective and convenient way to treat Alzheimer’s than infusions of antibodies.


Labels:

Comments

Post a Comment